



AbolerIS Pharma's co-founder Dr. Ignacio Anegon is promoted by the INSERM to the highest position in the French research system

NANTES, France, January 4th, 2021.

AbolerIS Pharma, a biotechnology company developing innovative immunotherapies, announces that Dr. Ignacio Anegon MD, was promoted by INSERM (the French national biomedical research institute) to the position of Directeur de Recherche de Classe Exceptionnelle (DRCE). INSERM promotes every year through a competitive selection from all disciplines few researchers to the DRCE position, the highest in the French research system. Ignacio Anegon did his medical studies in Uruguay, was post-doc at the University of Barcelona, Associate Scientist at the University of Pennsylvania and joined the INSERM in 1988. His DRCE promotion was based on his pioneer and leading work on the areas of immune tolerance as well as on the application of genome editing technologies. In the immunology area he developed new immune tolerance strategies based on the analysis of tolerogenic mechanisms by dendritic cells and CD8 regulatory T cells. In the genome editing field he has described new genome editing transgenic technologies and generated many lines of transgenic rats and lambs. He has been Director of the INSERM-Center for Research in Transplantation and Immunology (CRTI) in Nantes and group leader, he has also been Director of the Labex IGO and of the platform Transgenesis Rat ImmunoPhenomic platform. He also has positions in Boards of research centers, international academic societies and journals.

About AbolerIS Pharma. (<http://aboleris-pharma.com/>). AbolerIS Pharma is a recently created biotechnology company that develops new immunotherapies in the fields of autoimmune diseases, immune-mediated inflammatory diseases and transplantation. The company develops several molecules, such as the anti-CD45RC monoclonal antibody, a cytokine and other molecules are in its pipeline. Together with the optimization of its molecules, research and development are key sectors of AbolerIS Pharma activity. AbolerIS Pharma recently obtained seed investment for 2.5 M€ from Newton Biocapital and Turenne Santé/Sham Innovation Santé (<http://aboleris-pharma.com/wp-content/uploads/2020/11/press-release-seed-AbolerIS-Pharma-Vf.pdf>)

About CRTI. The CRTI is a joint research unit (UMR 1064) created by INSERM and Nantes Université (<http://www.itun.nantes.inserm.fr/>). The CRTI is located at the Nantes University Hospital where it constitutes with clinical departments the Institute of Transplantation Urology and Nephrology, one of the largest French and European kidney transplantation centers. The CRTI is part of the Labex Immunology Graft Oncology, a regional cluster of immunology laboratories and of the Nantes cluster of research (SFR). This unique environment fosters interactions between basic scientists and clinicians, supported by the most updated technological platforms and explains

the strong commitment of the CRTI to translational research. The long-term objectives of CRTI are to improve treatments and patient monitoring in transplantation and immune-mediated inflammatory diseases through understanding immune responses, developing new immunotherapeutics, biomarkers, tools for personalized medicine and alternative strategies for organ or tissue replacement.

For further information please contact:

Dr. Ann Meulemans (PhD), CEO

AbolerIS Pharma

e-mail : ann.meulemans@aboleris-pharma.com